MX2018002889A - Compuesto de pirimidina fusionada o sal del mismo. - Google Patents

Compuesto de pirimidina fusionada o sal del mismo.

Info

Publication number
MX2018002889A
MX2018002889A MX2018002889A MX2018002889A MX2018002889A MX 2018002889 A MX2018002889 A MX 2018002889A MX 2018002889 A MX2018002889 A MX 2018002889A MX 2018002889 A MX2018002889 A MX 2018002889A MX 2018002889 A MX2018002889 A MX 2018002889A
Authority
MX
Mexico
Prior art keywords
salt
compound
pyrimidine compound
ret
condensed pyrimidine
Prior art date
Application number
MX2018002889A
Other languages
English (en)
Inventor
Tadashi Shimamura
Hidenori Fujita
Miyazaki Isao
Kato Masanori
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MX2018002889A publication Critical patent/MX2018002889A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La presente invención proporciona un inhibidor de RET novedoso que comprende, como un ingrediente activo, un compuesto o una sal del mismo que no se conoce por su actividad inhibidora de RET, y también proporciona un agente para prevenir o tratar enfermedades (por ejemplo, tumores malignos) que pueden prevenirse o tratarse mediante actividad inhibidora de RET; el inhibidor de RET comprende, como un ingrediente activo, un compuesto representado por la fórmula (I) a continuación o una sal del mismo: (ver Fórmula) en donde A, R1 a R3, X, y n son como se definen en la especificación.
MX2018002889A 2015-09-08 2016-09-07 Compuesto de pirimidina fusionada o sal del mismo. MX2018002889A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015177073 2015-09-08
PCT/JP2016/076354 WO2017043550A1 (ja) 2015-09-08 2016-09-07 縮合ピリミジン化合物又はその塩

Publications (1)

Publication Number Publication Date
MX2018002889A true MX2018002889A (es) 2018-06-18

Family

ID=58239818

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002889A MX2018002889A (es) 2015-09-08 2016-09-07 Compuesto de pirimidina fusionada o sal del mismo.

Country Status (21)

Country Link
US (4) US10233189B2 (es)
EP (1) EP3260454B1 (es)
JP (1) JP6113379B1 (es)
KR (1) KR102058366B1 (es)
CN (1) CN108026101B (es)
AU (1) AU2016319525C1 (es)
CA (1) CA2996682C (es)
ES (1) ES2877537T3 (es)
HK (1) HK1254983A1 (es)
IL (1) IL257306B (es)
MA (1) MA41559A (es)
MX (1) MX2018002889A (es)
MY (1) MY192184A (es)
NZ (1) NZ739893A (es)
PH (1) PH12017502407A1 (es)
PL (1) PL3260454T3 (es)
RU (1) RU2729636C2 (es)
SG (1) SG11201800135WA (es)
TW (1) TWI675840B (es)
WO (1) WO2017043550A1 (es)
ZA (1) ZA201800218B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122019024201B1 (pt) 2010-05-20 2021-08-03 Array Biopharma Inc Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica
AU2016291676B2 (en) 2015-07-16 2020-04-30 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
IL261107B2 (en) 2016-02-23 2023-11-01 Taiho Pharmaceutical Co Ltd A novel compressed pyrimidine compound or a salt thereof
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
WO2019039439A1 (ja) 2017-08-21 2019-02-28 大鵬薬品工業株式会社 Ｄｃｔｎ１タンパク質とｒｅｔタンパク質との融合タンパク質
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
CN111630054B (zh) * 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
US11603374B2 (en) 2018-01-18 2023-03-14 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CA3087972C (en) 2018-01-18 2023-01-10 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
KR20200140302A (ko) 2018-04-05 2020-12-15 메르크 파텐트 게엠베하 타입 ii irak 억제제로서 헤테로아릴 화합물 및 이의 용도
JP2022500383A (ja) 2018-09-10 2022-01-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2023239422A2 (en) 2021-10-22 2023-12-14 University Of Houston System Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665721A (en) 1995-06-07 1997-09-09 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
UA80171C2 (en) 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
EP1687309A1 (en) 2003-11-17 2006-08-09 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
SI1696920T1 (sl) * 2003-12-19 2015-02-27 Plexxikon Inc. Spojine in postopki za razvoj modulatorjev ret
CA2575808A1 (en) 2004-08-02 2006-02-16 Osi Pharmaceuticals, Inc. Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
CA2631664C (en) * 2005-12-08 2012-05-08 Abbott Laboratories 9-membered heterobicyclic compounds as inhibitors of protein kinases
ES2562215T3 (es) * 2007-03-28 2016-03-03 Pharmacyclics Llc Inhibidores de la tirosina quinasa de Bruton
WO2011018894A1 (en) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
GB201201566D0 (en) * 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
US20160010068A1 (en) 2013-02-22 2016-01-14 Boris C. Bastian Fusion polynucleotides and fusion polypeptides associated with cancer and particularly melanoma and their uses as therapeutic and diagnostic targets
ES2646019T3 (es) * 2013-05-14 2017-12-11 Nerviano Medical Sciences S.R.L. Derivados de 6-amino-7-deaza-purina, proceso para su preparación y su uso como inhibidores de cinasa
CN105452257B (zh) 2013-08-12 2017-09-05 大鹏药品工业株式会社 新型稠合嘧啶化合物或其盐
WO2015078417A1 (zh) 2013-11-29 2015-06-04 四川好医生药业集团有限公司 吡咯并嘧啶化合物及其在制备降血糖药物中的用途
JP2015205555A (ja) 2014-04-18 2015-11-19 日立オートモティブシステムズ株式会社 組込制御システム
CA2997051C (en) 2015-09-01 2020-03-24 Taiho Pharmaceutical Co., Ltd. Novel pyrazolo[3,4-d]pyrimidine compound or salt thereof
IL261107B2 (en) 2016-02-23 2023-11-01 Taiho Pharmaceutical Co Ltd A novel compressed pyrimidine compound or a salt thereof

Also Published As

Publication number Publication date
EP3260454A4 (en) 2018-02-21
US20190092776A1 (en) 2019-03-28
AU2016319525A1 (en) 2018-01-25
CN108026101A (zh) 2018-05-11
CA2996682A1 (en) 2017-03-16
PL3260454T3 (pl) 2021-11-22
RU2018112252A3 (es) 2019-10-09
PH12017502407B1 (en) 2018-06-25
IL257306A (en) 2018-03-29
PH12017502407A1 (en) 2018-06-25
SG11201800135WA (en) 2018-02-27
MA41559A (fr) 2017-12-26
JP6113379B1 (ja) 2017-04-12
US11236096B2 (en) 2022-02-01
CA2996682C (en) 2021-01-12
WO2017043550A1 (ja) 2017-03-16
EP3260454A1 (en) 2017-12-27
IL257306B (en) 2021-07-29
US20200270260A1 (en) 2020-08-27
AU2016319525C1 (en) 2019-07-25
TW201716412A (zh) 2017-05-16
BR112018000698A2 (pt) 2018-09-18
RU2729636C2 (ru) 2020-08-11
ES2877537T3 (es) 2021-11-17
RU2018112252A (ru) 2019-10-09
TWI675840B (zh) 2019-11-01
HK1254983A1 (zh) 2019-08-02
NZ739893A (en) 2019-07-26
KR102058366B1 (ko) 2019-12-23
US20180009817A1 (en) 2018-01-11
EP3260454B1 (en) 2021-06-09
CN108026101B (zh) 2020-06-26
US10233189B2 (en) 2019-03-19
JPWO2017043550A1 (ja) 2017-09-07
AU2016319525B2 (en) 2019-01-31
MY192184A (en) 2022-08-05
US20200270261A1 (en) 2020-08-27
US11014930B2 (en) 2021-05-25
US10787457B2 (en) 2020-09-29
ZA201800218B (en) 2019-06-26
KR20180042368A (ko) 2018-04-25

Similar Documents

Publication Publication Date Title
MX2018002889A (es) Compuesto de pirimidina fusionada o sal del mismo.
SG11201806930PA (en) Novel condensed pyrimidine compound or salt thereof
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
MX2017009571A (es) Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer.
PH12015502018A1 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
PH12019500480A1 (en) Pyridine compound
MX2019003143A (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
PH12017502171B1 (en) PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
MX2014005928A (es) Inhibidores ciclicos de glutaminasa.
MX2015012822A (es) 3-pirimidin-4-il-oxazolidin-2-onas- como inhibidores del idh mutante.
PH12016502130B1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
MX2018001992A (es) Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa.
MX351863B (es) Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo.
MX2017000521A (es) Pirimidinas novedosas 2,5-sustituidas como inhibidores de pde4.
MX2017000522A (es) Pirimidinas novedosas 2,5-sustituidas como inhibidores de pde.
PH12016500735A1 (en) Substituted pyrimidine compounds and their use as syk inhibitors
MY197518A (en) Preventive and/or therapeutic agent of immune disease
MY192305A (en) Bipyrazole derivatives as jak inhibitors